European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 139, Issue 1 , Pages 3-10 , July 2008

Maternal venous thrombosis

  • Peter Clark

      Affiliations

    • Corresponding Author InformationTel.: +44 1382 647716; fax: +44 1382 642551.

Received 19 August 2007 ,Revised 12 February 2008 ,Accepted 22 February 2008.

References 

  1. Gherman R, Goodwin T, Leung B, et al. Incidence, clinical characteristics and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999;94:730–734
  2. Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol. 1999;94:595–599
  3. Bergqvist A, Bergqvist D, Hallbook T. Deep vein thrombosis during pregnancy. A prospective study. Acta Obstet Gynecol Scand. 1983;62:443–448
  4. McColl M, Ramsay J, Tait R, et al. Risk factors for pregnancy-associated venous thromboembolism. Thromb Haemost. 1997;78:1183–1188
  5. Confidential Enquiries into Maternal and Child Health. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer – 2000–2005. London: CEMACH; 2007.
  6. Chang J, Elam-Evans L, Berg C. Pregnancy-related mortality surveillance – United States 1991–1999. MMWR Surveill Summ 2003. 2003;52:1–8
  7. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003;17:S1–S5
  8. Lwaleed B, Bass P. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 2006;208:327–339
  9. Bayston T, Lane D. Antithromb molecular basis of deficiency. Thromb Haemost. 1997;78:339–343
  10. Esmon C. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006;32:49–60
  11. Clark P. Changes in haemostasis variables in pregnancy. Semin Vasc Med. 2003;3:13–24
  12. Clark P. Effect of pregnancy on the hemostatic and metabolic systems. In:  Greer I,  Ginsberg J,  Forbes C editor. Women's vascular health. London: Hodder Arnold; 2007;
  13. Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost. 1998;79:1166–1170
  14. Espana F, Gilabert J, Aznar J, Estelles A, Kobayashi T, Griffin JH. Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia. Am J Obstet Gynecol. 1991;164:1310–1316
  15. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J Int Med. 1992;232:155–160
  16. Anderson F, Wheeler H, Goldberg R. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Int Med. 1991;151:933–938
  17. Brill-Edwards P, Ginsberg J, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism Recurrence of clot in this pregnancy study group. New Engl J Med. 2000;343:1439–1444
  18. Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost. 2005;3:949–954
  19. De Stefano V, Martinelli I, Rossi E, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol. 2006;135:386–391
  20. Tengborn L, Bergqvist D, Matzsch T, et al. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?. Am J Obstet Gynecol. 1989;160:90–94
  21. Simioni P, Tormene D, Prandoni P, Girolami A. Pregnancy-related recurrent events in thrombophilic women with previous thromboembolism. Thromb Haemost. 2001;86:929
  22. Ray J, Chan W. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obst Gynecol Surv. 1999;54:265–271
  23. Macklon N, Greer I, Bowman A. An ultrasound study of gestational and posterial changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol. 1997;104:191–197
  24. Bates S, Greer I, Hirsh J, Ginsberg J. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:S627–S644
  25. RCOG Green Top Guideline Number 37. Thromboprophylaxis during pregnancy, labour and delivery. London: RCOG; 2004.
  26. Simpson E, Lawrenson R, Nightingale A, Farmer R. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. Br J Obstet Gynaecol. 2001;108:56–60
  27. Waterstone J, Summers B, Hoskins M, Berry J, Parsons J. Ovarian hyperstimulation syndrome and deep cerebral venous thrombosis. Br J Obstet Gynaecol. 1992;99:439–440
  28. Arya RSH, Patel H, et al. Internal jugular vein thrombosis after assisted conception therapy. Br J Haematol. 2001;115:153–155
  29. McColl M, Tait R, Greer I, Walker I. Injecting drug use is a risk factor for deep vein thrombosis in women in Glasgow. Br J Haematol. 2001;112:641–643
  30. Aessopos A, Stamatelos G, Skoumas V, Vassilopoulos G, Mantzourani M, Loukopoulos D. Pulmonary hypertension and right heart failure in patients with β-thalassemia intermedia. Chest. 1995;107:50–53
  31. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2005;132:244–245
  32. Steward G, Amess J, Eber S, et al. Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol. 1996;93:303–310
  33. Schwarz T, Siegert G, Oettler W, et al. Venous thrombosis after long-haul flights. Arch Intern Med. 2003;163:2759–2764
  34. Bertina R, Koeleman B, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67
  35. Rosendaal F, Koster T, Vandenbroucke J, Reitsma P. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504–1508
  36. Folsom A, Cushman M, Tsai MY, et al. A prospective study of venous thromboembolism in relation to factor V leiden and related factors. Blood. 2002;99:2720–2725
  37. Poort S, Rosendaal F, Reitsma P, Bertina R. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703
  38. Rosendaal F, Doggen C, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706–708
  39. Emmerich J, Rosendaal F, Cattaneo M, et al. Study group for pooled analysis in venous thromboembolism Combined effect of factor V leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case–control studies including 2310 cases and 3204 controls. Thromb Haemost. 2001;86:809–816
  40. Chinthammitr Y, Vos H, Rosendaal F, Doggen C. The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: results of the MEGA study, a large population-based case–control study. J Thromb Haemost. 2006;4:2587–2592
  41. Wu O, Bayoumi N, Vickers M, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost. 2008;6:62–69
  42. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132:171–196
  43. Dykes A, Walker ID, McMahon A, Islam S, Tait R. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol. 2001;113:636–641
  44. Tait R, Walker I, Reitsma P, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995;73:87–93
  45. Miletich J, Sherman L, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. New Eng J Med. 1987;317:991–996
  46. Martinelli I, Mannucci P, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92:2353–2358
  47. Simioni P, Sanson B, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81:198–202
  48. Vossen C, Conard J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost. 2004;2:1526–1532
  49. Rosenberg R. Actions and interactions of antithrombin and heparin. New Engl J Med. 1975;292:146–151
  50. Odegard O, Abildgaard U. Antithrombin III Critical review of assay methods. Significance of variations in health and disease. Haemostasis. 1978;7:127–134
  51. Tait R, Walker I, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994;87:106–112
  52. Clark P, Walker ID. The phenomenon known as acquired activated protein C resistance. Br J Haematol. 2001;115:767–773
  53. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15:145–151
  54. Miyakis S, Lockshin M, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306
  55. Gerhardt A, Scharf R, Beckman M, et al. Prothrombin and factor V mutations in women with thrombosis during pregnancy and the puerperium. New Engl J Med. 2000;342:374–380
  56. Walker I, Greaves M, Preston F. British Society for Haematology guideline: investigation and management of heritable thrombophilia. Br J Haematol. 2001;114:512–528
  57. Kent N, Leduc L, Crane J, et al. SOGC Clinical Practice Guideline: prevention and treatment of venous thromboembolism (VTE) in obstetrics. J Soc Obstet Gynaecol Can. 2000;22:736–742
  58. American College of Obstetricians Gynecologists Committee on Practice Bulletins . Obstetrics: thromboembolism in pregnancy. Int J Gynecol Obstet. 2001;75:203–212
  59. Wells P, Anderson D, Bormanis J, et al. Value of assessment of pretest probability of deep vein thrombosis in clinical management. Lancet. 1997;350:1795–1798
  60. Chan W, Ginsberg J. Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy. Thromb Res. 2002;107:85–91
  61. Kearon C, Ginsberg J, Hirsch J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Int Med. 1998;129:1044–1049
  62. Kearon C, Julian J, Newman T, Ginsberg J. Non-invasive diagnosis of deep venous thrombosis McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Int Med. 1998;128:663–667
  63. Birdwell B, Raskob G, Whitsett T. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Int Med. 1998;128:1–7
  64. Ginsberg J, Hirsch J, Rainbow A, et al. Risks to the fetus of radiological procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost. 1989;61:189–196
  65. Scarsbrook A, Gleeson F. Investigating suspected pulmonary embolism in pregnancy. Br Med J. 2007;334:418–419
  66. Juni J, Alavi A. Lung scanning in the diagnosis of pulmonary embolism. The emperor redressed. Semin Nucl Med. 1991;21:281–296
  67. Cook J, Kyriou J. Radiation from CT and perfusion scanning in pregnancy. Br Med J. 2005;331:350
  68. Nijkeuter M, Geleijns J, De Roos A, Meinders A, Huisman M. Diagnosing pulmonary embolism in pregnancy: rationalising fetal radiation exposure in radiological procedures. J Thromb Haemost. 2004;2:1857–1858
  69. Winer-Muram H, Boone J, Brown H, Jennings S, Mabie W, Lombardo G. Pulmonary embolism in pregnant patients: fetal radiation dose with helical CT. Radiology. 2002;224:487–492
  70. Parker M, Hui F, Camacho M, Chung J, Broga D, Sethi N. Female breast radiation exposure during CT pulmonary angiography. Am J Roentgenol. 2005;185:1228–1233
  71. Remy-Jardin M, Remy J. Spiral CT angiography of the pulmonary circulation. Radiology. 1999;212:615–636
  72. Allen C, Demetriades T. Radiation risk overestimated. Radiology. 2006;240:613–614
  73. Ginsberg J, Hirsh J, Turner C, Levine M, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost. 1989;61:197–203
  74. Vitale N, De Feo M, De Santo L, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999;33:1637–1641
  75. Chan W, Anand S, Ginsberg J. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Int Med. 2000;160:191–196
  76. Wesseling J, van Driel D, Heyman H, et al. Coumarins during pregnancy: long term effects on growth and development in school age children. Thromb Haemost. 2001;85:609–613
  77. Hirsch J, Cade J, Gallus A. Fetal effects of coumadin administration during pregnancy. Blood. 1970;36:623–627
  78. Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res. 1984;34:557–560
  79. Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost. 1987;57:234
  80. Flessa HC, Klapstrom AB, Glueck HI, Will JJ. Placental transport of heparin. Am J Obstet Gynecol. 1965;93:570–573
  81. Greer I, Nelson-Piercy C. Low-molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401–407
  82. Warkentin T, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl. 3):311S–337S
  83. RCOG Green Top Guideline Number 28. Thromboembolic disease in pregnancy and the puerperium: acute management. London: RCOG; 2007.
  84. Douketis J, Ginsberg J, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density A prospective matched cohort study. Thromb Haemost. 1996;75:254–257
  85. Dahlman T. Osteporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168:1265–1270
  86. Monreal M, Lafoz E, Olive A, del Rio L, Vedra C. Comparison of subcutaneous unfractionated heparin with low molecular weight heparin (fragmin) in patients with venous thromboembolism and contraindications for coumarin. Thromb Haemost. 1994;71:7–11
  87. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Post partum bone mineral density in women treated or thromboprophylaxis with unfractionated or LMW heparin. Thromb Haemost. 2002;87:182–186
  88. Rodger M, Kahn S, Cranmey A, et al. Long-term dalteparin in pregnancy is not associated with a decrease in bone mineral density: substudy of a randomised controlled trial. J Thromb Haemost. 2007;5:1600–1606
  89. Dolovich L, Ginsberg J, Douketis J, Holbrook A, Cheah G. A meta-analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism: some unanswered questions regarding location of treatment, product type and dosing frequency. Arch Int Med. 2000;160:181–188

PII: S0301-2115(08)00069-9

doi: 10.1016/j.ejogrb.2008.02.011

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 139, Issue 1 , Pages 3-10 , July 2008

Article Tools